Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Levothyroxine

Preparation Calculator

USE IF: Hypothyroidism replacement, post-thyroidectomy replacement, selected TSH-suppression protocols β€” with TSH/T4 monitoring, absorption hygiene, and clear distinction from myxedema coma pathways.

AVOID IF: Untreated thyrotoxicosis; dose titration driven only by symptoms without labs; ignoring absorption timing with iron/calcium/feeds/PPIs when control is unstable.

Levothyroxine

Thyroid hormone replacement (T4)

AdultPediatricEndocrineThyroidClinicWardPerioperative

Indication

Hypothyroid replacement β€’ Post-thyroidectomy β€’ Cancer TSH suppression (selected) β€’ Myxedema coma (IV, protocol/ICU)

At a glance

INDICATIONS (CORE USE)

- Hypothyroidism - Post-thyroidectomy replacement - TSH suppression in selected thyroid cancer protocols

ADULT DOSE (STANDARD)

Healthy adult replacement often ~1.6 mcg/kg/day PO (individualize) Elderly / CAD / frail: start 12.5–25 mcg daily β†’ titrate slowly Mild / subclinical / partial replacement: lower starts when indicated

MAX DOSE

Individualized β€” no simplistic universal max; unusually high doses / suppression therapy β†’ specialist oversight

Route

PO (main); IV in selected severe inpatient settings (protocol/specialist)

PEDIATRIC DOSE

Weight-based; endocrine-guided only

Do not miss

Must-not-miss safety points

Major warning

- Severe hypothyroidism / myxedema coma β†’ emergency escalation; oral outpatient logic does not apply - Overtreatment β†’ tachyarrhythmia / angina / bone loss risk - Undertreatment β†’ persistent hypothyroid symptoms; pregnancy and cardiac patients are high-risk contexts - Absorption is highly interaction-sensitive (iron, calcium, PPIs, feeds, food) - Dose changes should be TSH / free T4 guided, not symptom-only

Indications

Primary

  • Hypothyroidism
  • Post-thyroidectomy replacement
  • TSH suppression in selected thyroid cancer protocols

Secondary

  • Myxedema coma (IV, protocol-guided, specialist/ICU context)

Other

  • Selected endocrine replacement contexts

Dosing

STANDARD (ADULT PO)

Healthy adult replacement often ~1.6 mcg/kg/day PO (individualize) Elderly / CAD / frail: start 12.5–25 mcg daily β†’ titrate slowly Mild / subclinical / partial replacement: lower starting doses when clinically indicated

ADULT DOSE

Use the same brand/formulation consistently when possible Titrate on TSH / free T4 β€” not day-to-day symptoms alone Recheck usually ~6 weeks after dose change

PEDIATRIC DOSE

Weight-based; endocrine-guided only

MAX DOSE

Individualized; avoid a single hard universal max β€” specialist oversight for unusually high doses or suppression therapy

Practical Note

- Myxedema coma: IV + ICU/endocrine protocol β€” not outpatient oral titration logic - CAD / elderly: low start, slow escalation; watch HR / angina - Pregnancy: requirements often rise early β€” reassess promptly with tighter targets - Formulation switch may shift control β€” schedule lab follow-up

Warnings

Clinical warnings

  • Overtreatment β†’ tachycardia, AF, angina, tremor, weight loss
  • Undertreatment β†’ persistent hypothyroid burden
  • CAD / elderly β†’ slower titration
  • Absorption vulnerable to food, calcium, iron, enteral feeds, gastric-acid modifiers
  • Formulation changes may alter steady state β€” reassess with labs

Contraindications

  • Untreated thyrotoxicosis
  • Known hypersensitivity to formulation components

Drug interactions

  • Calcium / iron supplements β†’ reduced absorption (separate dosing)
  • Enteral tube feeds β†’ reduced absorption (hold / separate per protocol)
  • PPIs / acid-lowering therapy β†’ may alter absorption (monitor TSH/T4 if unstable)
  • Warfarin β†’ anticoagulant effect may shift as thyroid status normalizes or overtreats
  • Enzyme inducers (e.g., selected anticonvulsants, rifampin) β†’ may increase dose requirement

Special populations

Pediatrics

Weight-based; endocrine-guided only

Pregnancy

Pregnancy: requirements often increase early β€” reassess promptly; maintain tighter thyroid control per obstetric/endocrine protocols.

Lactation

compatible at physiologic replacement; verify local guidance if on suppressive doses.

Renal impairment

No routine isolated renal dose adjustment β€” titrate to TSH / free T4 and clinical context.

Hepatic impairment

No routine isolated hepatic dose adjustment β€” peripheral T4β†’T3 conversion varies; titrate to labs.

Elderly

Elderly: start low, titrate slowly. Cardiac disease (CAD, ischemic risk): low starting dose; avoid rapid escalation; monitor HR and angina.

Administration

- PO on empty stomach, same time daily - Separate from iron / calcium and other major binding interactions - Keep formulation consistent when possible - PO ↔ IV conversion in severe inpatient context: protocol / specialist guidance only

Monitoring

  • Monitor: - Symptoms / clinical response - TSH - Free T4 when clinically relevant or in special contexts - HR / angina symptoms in cardiac-risk patients
  • Recheck: - About 6 weeks after initiation or dose/formulation change - Reassess earlier in pregnancy or severe instability when clinically required
  • Hold / reassess: - Overtreatment signs (tachyarrhythmia, angina, tremor, clear thyrotoxic symptoms) - Major formulation / absorption change without a lab reassessment plan

Overdose / toxicity

Clinical Picture

Thyrotoxic symptoms Tachycardia / arrhythmia Agitation / tremor Delayed toxicity possible

Immediate Actions

Stop or hold drug Supportive care ECG / cardiac monitoring if significant exposure or symptoms Treat severe adrenergic symptoms per protocol

Antidote

No specific antidote β€” supportive care

Decontamination

Acute overdose: supportive care; poison center if massive ingestion or unstable patient.

Escalation

Hemodynamic instability, severe arrhythmia, or ICU-level thyrotoxic storm features β†’ escalate per endocrine/ICU pathway.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Recheck at ~6 weeks, not in a few days
  • Most dose failures = absorption / adherence / formulation β€” not always β€œneed more mcg”

Clinical

  • In CAD / elderly: start low and go slow
  • Pregnancy often needs earlier dose increase / earlier reassessment

Safety

  • Do not chase symptoms alone without thyroid labs

Pharmacy Tool

Preparation Calculator

Levothyroxine 25 mcg/mL oral suspension

suspension Β· oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Long half-life - Hepatic / peripheral conversion to T3 - Slow achievement of steady state

Mechanism of action

- Synthetic thyroxine (T4) replacement

Common brand names

Saudi Arabia

Eltroxin, Euthyrox, Levothyrox

Global

Synthroid, Levoxyl, Tirosint, (placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ATA / AACE thyroid hormone replacement and pregnancy guidance (where applicable)
  • Post-thyroidectomy and thyroid cancer follow-up protocols (institutional / ATA where applicable)
  • BNF / local formulary
  • FDA / SFDA product labeling